Tianjin Pharmaceutical Da Ren Tang Group (SHA:600329, SGX:T14) expects to post a net profit attributable to the parent of between 2.15 billion yuan and 2.39 billion yuan in 2024, soaring from 118% to 142% year on year, according to a Shanghai Stock Exchange disclosure on Monday.
The Chinese pharmaceutical company's attributable profit a year ago was 986.7 million yuan or 1.28 yuan per share.
The company attributed the forecast to a 1.71 billion yuan income generated from the disposal of a 13% stake in joint venture Sino-US Tianjin SmithKline Pharmaceutical.
Tianjin Pharma's shares rose less than 2% in recent trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。